The present invention generally relates to fat grafting procedures and more specifically relates to devices and methods for combining and dispensing adipose tissue and biocompatible additives for use in fat grafting procedures.
Autologous fat transfer (AFT), also known as fat grafting, is a process by which fat is harvested from one part of a human body and injected into another part of the same person's body where additional bulk may be needed or desired for cosmetic and/or aesthetic purposes. Clinical applications for autologous fat transfer are expanding rapidly with recent reported use in breast reconstruction and augmentation, buttock enhancement, treatment of congenital tissue defects, facial reconstruction, and skin rejuvenation. Although this is a very attractive approach and there is an increased trend in replacement of soft tissue volume with AFT, typical survival rates of grafted fat may be poor and overall results may not be satisfactory.
U.S. Patent Application Publication No. 20110202014 discloses a fat graft syringe assembly for delivering small amounts of fat graft material to treat delicate anatomical areas.
WO 2008148071 discloses kits, tools, and methods are described for harvesting, processing, and using injectable dermis in volume filling procedures.
WO 200903135 discloses system for harvesting fat through liposuction, concentrating the aspirate so obtained, and then re-injecting the concentrated fat into a patient.
There still remains a need for improved devices and methods for use in fat grafting procedures.
Accordingly, a device for introducing into a target region of a patient, a combination of adipose tissue and an additive, is provided. The device generally comprises a fat cartridge for containing an amount of processed or unprocessed adipose tissue or adipose derived material, and an additive cartridge for containing an additive to be combined with the adipose material. The device further comprises a housing configured to receive, for example, in a side-by-side manner, the fat cartridge and additive cartridge, and a mixing tip on the housing, the mixing tip including a distal end for receiving a cannula or needle. The device further comprises a plunger assembly including a fat cartridge plunger and an additive cartridge plunger, configured to be slidably received in the fat cartridge and the additive cartridge, respectively, and for applying force to the contents of the respective cartridges for moving the contents into the mixing tip and eventually out of the cannula or needle.
In some embodiments, the fat cartridge plunger and the additive cartridge plunger are fixed with respect to each other, for example, at a proximal end of the plunger assembly.
In some embodiments, the housing is configured to receive the fat cartridge and the additive cartridge in a longitudinally slidable manner. In other embodiments, the housing is configured to receive the fat cartridge and the additive cartridge in a lateral manner.
In one aspect of the invention, the device further comprises a mechanism for preventing extrusion of additive from the additive cartridge without coextrusion of fat from the fat cartridge.
In another aspect of the invention, a device is provided for administering a formulation comprising an adipose tissue and an additive wherein the device generally comprises (a) a first cartridge for containing an adipose tissue, (b) a second cartridge for containing an additive to be added to and mixed with the adipose tissue and (c) a housing configured to substantially enclose in a side-by-side manner the first and the second cartridges. In addition, the device comprises (d) a mixing tip on the housing, wherein the mixing tip includes (i) a chamber or lumen, (ii) a proximal end for receiving and conducting into the lumen the adipose tissue and the additive for mixing within the lumen, and (iii) a distal end for receiving a cannula or needle through which the formulation can be administered. Further still, the device may comprise (e) a plunger assembly including a first cartridge plunger and a second cartridge plunger, the plunger assembly configured to be slidably received in the first cartridge and in the second cartridge and the plunger assembly when actuated acting to push the adipose tissue, by the action of the first cartridge plunger, from the first cartridge into the lumen and to push the additive, by the action of the second cartridge plunger, from the second cartridge into the lumen, for the mixing therein.
Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent.
The present invention may be more clearly understood and the advantages thereof better appreciated by considering the below Detailed Description and accompanying Drawings of which:
Referring now to
The device 10 generally comprises a first cartridge 12, hereinafter sometimes referred to as a fat cartridge 12, for containing an amount of processed or unprocessed adipose tissue or adipose derived material, and a second cartridge 18, hereinafter sometimes referred to as an additive cartridge 18, for containing an additive 20 to be combined with the adipose tissue 14.
The adipose tissue may be in the form of freshly harvested or processed lipoaspirate, including adipocytes, adipose-derived stem cells, stromal vascular fraction cells, or combinations thereof.
Additives useful in within the scope of the present devices may be any material that may be mixed with cellular material, for example, living cells, for example, adipose tissue including adipose cells, and which is beneficial to maintaining the viability of the cellular material when mixed therewith and then injected or implanted in a body. Such additives may be in the form of hydrogels that enhance, promote or support cell proliferation or survival. Additives useful in the present devices are described, for example, in commonly owned U.S. Provisional Patent Application No. 61/586,589, filed on Jan. 13, 2012, and entitled CROSSLINKED HYALURONIC ACID-COLLAGEN MATRICES FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION, and U.S. patent application Ser. No. 13/740,712, filed on Jan. 14, 2013, the entire disclosure of each of these documents being incorporated herein by this reference.
When injected or implanted in vivo, the hydrogel or a hydrogel composition may promote cell and/or tissue growth, including growth into the implant material. For example, a hydrogel or hydrogel composition may stimulate angiogenesis, neovascularization, adipogenesis, collagenesis, cell infiltration, tissue integration, and the like in vivo. Once injected or implanted into a soft tissue using the devices of the present invention, a combined hydrogel composition and fat material may stimulate angiogenesis, neovascularization, adipogenesis, and/or collagenesis. The hydrogel composition may comprise a hyaluronic acid component and a collagen component, for example, a hyaluronic acid component crosslinked to a collagen component.
Turning back now to
In the shown embodiment, the fat cartridge 12 and additive cartridge 18 include luer end 27, 28, respectively. The housing is configured to hold two distinct, for example, different, cartridge sizes, as shown. In one embodiment, the volume ratio of fat cartridge to additive cartridge is about 2:1, up to about 5:1. For example, in the shown embodiment, the fat cartridge 12 may be sized to contain between about 5 ml to about 60 ml, or more, of material, and the additive cartridge 18 may be sized to contain between about 1 ml to about 30 ml of material. Other ratios and sizes are contemplated and are considered to be within the scope of the present invention.
The device 10 may further include a tip 30 coupled to or integral with a distal end 32 of the housing 26. The tip 30 generally includes a lumen or chamber 36, a proximal end for receiving and conducting into the lumen 36 the adipose tissue 14 and the additive 20, which may be mixed or combined within the lumen 36. The tip 30 further includes a distal end structured for receiving a cannula or needle, for example, more specifically, a needle hub. Formulation comprising a mixture of adipose tissue and additive may be passed from the tip lumen 36 into the needle or cannula 40 and thereby administered to a patient. The tip 30 includes a distal end 34 for receiving a cannula or needle 40, for example, more specifically, a needle hub. The tip lumen or chamber 36 may be structured to cause mixing or combining of fat and additive as these materials are passed through the chamber 36 and into the cannula or needle 38. Suitable needle and cannula gauges useful in the present invention include, but are not limited to, for example, 14 gauge up to 32 gauge needle/cannulas. Needle/cannulas may be blunt end or sharp.
The device 10 further comprises a plunger assembly 40 including a fat cartridge plunger 42 and an additive cartridge plunger 44, configured to be slidably received in the fat cartridge 12 and the additive cartridge 18, respectively, and for applying force to the contents of the respective cartridges 12, 18 for moving the contents 14, 20 into the tip 30 and eventually out of the cannula or needle 38 and into a patient.
In this shown embodiment, the plunger assembly 40 is a unitary structure, for example, a unitary molded structure, with proximal portion 46 providing a coupling region between fat cartridge plunger 42 and additive cartridge plunger 44. Proximal portion 46 may be configured as a planar surface, a concave or convex surface, to accommodate a thumb of an operator of the device 10. As shown, the plunger assembly 40 may be configured to be slidably received in the first cartridge 12 and in the second cartridge 18 and the plunger assembly 40 when actuated acting to push the adipose tissue 14, by the action of the first cartridge plunger 42, from the first cartridge 12 into the tip lumen 36 and to push the additive 20, by the action of the second cartridge plunger 44, from the second cartridge 18 into the lumen 36, for the mixing therein.
For each fat grafting procedure, the fat cartridge 12 is filled with freshly harvested or processed adipose tissue and placed into or engaged with the housing 26. The additive cartridge 18 is filled with an additive is also placed into the housing 26. A housing top cover 48 is snapped over the two cartridges 12, 18 securing them firmly in place in the housing 26. The tip 30 is snapped onto the housing 26 using a suitable mechanism, for example, o-rings 52, to seal fat cartridge luer end 27 and additive cartridge luer end 28 to the tip 30.
In use, an operator loads the fat cartridge 12 containing freshly harvested and/or prepared fat, into the fat cartridge 12. The additive cartridge 18 may already be in place in the housing 26, or the operator engages the additive cartridge 18 with the housing 26 just prior to the procedure. The housing top cover 48 is snapped into the housing 26 which is engaged to the mixing tip 30. The plunger assembly 40 is inserted into the cartridges 12, 18. The operator places the needle or cannula tip into a target region of the patient and presses the proximal portion 46 of the plunger assembly 40 to cause extrusion of fat and additive into the target region.
In some embodiments, the tip 30 may be modular in that it can be provided in a variety of different configurations allowing for a variety of mixing configurations and requirements. In some embodiments, for example, the tip 30 is configured to include mixing elements such as helical static mixers, grooves, pins, or other structure within the chamber 36 to effect mixing of the fat and additive as these are being extruded through chamber 36.
Turning now to
Device 110 is similar to device 10 shown in
For example, for each surgical procedure, mixing tip 30′ is snapped onto the open-sided housing 60. Additive cartridge 18 containing additive is inserted into the housing 60 through proximal end thereof, and is rotated until the luer feature 66 engage and tighten into the corresponding coupling structure 70 on tip 30′. Similarly, the fat cartridge 12 can be inserted into the housing 60 and snapped or rotated in place. The fat cartridge 12 seats into the tip 30′ and uses the interference between luer end of the fat cartridge 12 and the corresponding connector 68 of tip 30′ for creating a seal therebetween. Needle or cannula 38 may be installed to the tip 30 in a usual manner.
Also shown in
Turning now to
For example, for each surgical procedure, tip 30′ is snapped onto the housing 88. Cartridge 18 containing additive 20 is placed into the housing 88 by either snapping the cartridge 18 straight in from the side, or by slipping the luer end 66 into side opening of housing 88, then snapping the proximal end of cartridge 18 into the proximal end of housing 88. The cartridge 18 may then be pressed or rotated until it tightens into the tip 30′. The fat cartridge 12 containing adipose material 14 can then be snapped into the housing 88 in a similar manner. The fat cartridge 12 seats into the tip 30′ and uses the interference between the existing luer center protrusions of the fat cartridge and the tip 30′ for a seal. Manual pressing of the proximal end 80 of plunger assembly 72 causes extrusion of cartridge contents 14, 20 through needle or cannula 38.
Turning now to
Turning now to
For example, tip 30a may be provided which includes suitable structure effective to mix or combine the fat material 1 with the additive 2 as these materials 1, 2 are passed through tip 30a immediately prior to extrusion from needle or cannula 38. Alternatively, tip 30b may be provided which is structured to extrude fat material 1 and additive 2 without substantial or significant mixing. Alternatively still, tip 30c may be provided which is structured to provide a co-extrusion of fat material 1 and additive 2, as shown. Although not shown, it can be appreciated that tip 30c may be configured to provide a coextrusion with fat 1 surrounded by additive 2, rather than as shown (additive 2 surrounded by fat 1).
Other tips and structure useful as components of the present devices 10, 110, 210, 310 are disclosed in U.S. patent application Ser. No. 12/909,216, filed on Oct. 21, 2010, and entitled DUAL CARTRIDGE MIXER SYRINGE, the entire disclosure of which is incorporated herein by this specific reference.
In another aspect of the invention, the device 10, 110, 210, 310 may include a mechanism for discouraging or preventing tampering or misuse of product.
For example, as mentioned hereinabove, the additive cartridge may be permanently fixed in the housing to prevent removal without destruction of the device.
Alternatively or additionally, as illustrated in
For example, the tip 30 or 30′ may be provided with a valve 104. Valve 104 includes geometry that allows opening of the additive injection channel only when engineered pressures are induced. Typically air, a highly compressive medium is unable to create a sufficient spike in pressure to rotate the valve and allow dispensing of additive. Alternatively, a medium like fat, a non-compressive medium, is able to create the pressure spike and rotate the valve for additive injection. In other embodiments, the valve could involve flaps, diaphragms, pinches, or other means to achieve the same function. Valve 104 is structured to remain sealed or closed in the event that only air pressure is applied to the fat cartridge valve seat. Thus, the valve 104 would prevent dispensing of additive alone.
While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the invention.
This application claims priority to U.S. Provisional Patent Application No. 61/683,157, filed Aug. 14, 2012 the entire contents of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2737946 | Hein, Jr. | Mar 1956 | A |
2853070 | Maurice | Sep 1958 | A |
D202754 | Naftolin | Nov 1965 | S |
D214112 | Langdon | May 1969 | S |
D224066 | McDonald | Jun 1972 | S |
3720211 | Kyrias | Mar 1973 | A |
3767085 | Cannon et al. | Oct 1973 | A |
3807048 | Malmin | Apr 1974 | A |
4240423 | Akhavi | Dec 1980 | A |
4240426 | Akhavi | Dec 1980 | A |
4273122 | Whitney et al. | Jun 1981 | A |
4326517 | Whitney et al. | Apr 1982 | A |
4529401 | Leslie et al. | Jul 1985 | A |
4699612 | Hamacher | Oct 1987 | A |
D303010 | Jabbusch | Aug 1989 | S |
4869717 | Adair | Sep 1989 | A |
5024656 | Gasaway et al. | Jun 1991 | A |
5046506 | Singer | Sep 1991 | A |
5100390 | Lubeck et al. | Mar 1992 | A |
5104375 | Wolf et al. | Apr 1992 | A |
5127436 | Campion et al. | Jul 1992 | A |
5141496 | Dalto et al. | Aug 1992 | A |
5295980 | Ersek | Mar 1994 | A |
5305788 | Mayeux | Apr 1994 | A |
5322511 | Armbruster et al. | Jun 1994 | A |
5344407 | Ryan | Sep 1994 | A |
5383851 | Mackinnon, Jr. et al. | Jan 1995 | A |
5405330 | Zunitch et al. | Apr 1995 | A |
D378939 | Smith et al. | Apr 1997 | S |
5690618 | Smith et al. | Nov 1997 | A |
5817033 | DeSantis et al. | Oct 1998 | A |
D424194 | Holdaway et al. | May 2000 | S |
D441077 | Garito et al. | Apr 2001 | S |
6231552 | Jentzen | May 2001 | B1 |
6432046 | Yarush et al. | Aug 2002 | B1 |
6613010 | Castellano | Sep 2003 | B2 |
6616448 | Friedman | Sep 2003 | B2 |
D483116 | Castellano | Dec 2003 | S |
6689095 | Garitano et al. | Feb 2004 | B1 |
6783514 | Tovey et al. | Aug 2004 | B2 |
6824526 | Castellano | Nov 2004 | B2 |
7018356 | Wise et al. | Mar 2006 | B2 |
7419472 | Hibner et al. | Sep 2008 | B2 |
7494473 | Eggers et al. | Feb 2009 | B2 |
D615192 | Mudd et al. | May 2010 | S |
7878981 | Strother et al. | Feb 2011 | B2 |
D637287 | Mudd et al. | May 2011 | S |
8029460 | Rush et al. | Oct 2011 | B2 |
8066629 | Dlugos | Nov 2011 | B2 |
8480630 | Mudd et al. | Jul 2013 | B2 |
8603028 | Mudd et al. | Dec 2013 | B2 |
20020010433 | Johnson et al. | Jan 2002 | A1 |
20020151843 | Correa et al. | Oct 2002 | A1 |
20030144632 | Hommann et al. | Jul 2003 | A1 |
20030199883 | Laks | Oct 2003 | A1 |
20040092927 | Podhajsky et al. | May 2004 | A1 |
20040147883 | Tsai | Jul 2004 | A1 |
20050085767 | Menassa | Apr 2005 | A1 |
20050131353 | Mossanen-Shams et al. | Jun 2005 | A1 |
20050137496 | Walsh et al. | Jun 2005 | A1 |
20050261633 | Khalaj | Nov 2005 | A1 |
20060079765 | Neer | Apr 2006 | A1 |
20060089594 | Landau | Apr 2006 | A1 |
20070083155 | Muller | Apr 2007 | A1 |
20070100363 | Dollar et al. | May 2007 | A1 |
20070212385 | David | Sep 2007 | A1 |
20070250010 | Hohlfelder et al. | Oct 2007 | A1 |
20080033347 | D'Arrigo et al. | Feb 2008 | A1 |
20080071385 | Binette et al. | Mar 2008 | A1 |
20080097325 | Tanaka et al. | Apr 2008 | A1 |
20080108952 | Horvath et al. | May 2008 | A1 |
20080188816 | Shimazaki et al. | Aug 2008 | A1 |
20080200758 | Orbay et al. | Aug 2008 | A1 |
20090088703 | Azar | Apr 2009 | A1 |
20090124996 | Heneveld et al. | May 2009 | A1 |
20090143746 | Mudd et al. | Jun 2009 | A1 |
20090240200 | Heneveld et al. | Sep 2009 | A1 |
20090299328 | Mudd et al. | Dec 2009 | A1 |
20100069848 | Alferness et al. | Mar 2010 | A1 |
20100152675 | McClintock | Jun 2010 | A1 |
20100152679 | Tezel et al. | Jun 2010 | A1 |
20100280488 | Pruitt et al. | Nov 2010 | A1 |
20100282774 | Greter et al. | Nov 2010 | A1 |
20110021905 | Patrick et al. | Jan 2011 | A1 |
20110092916 | Tezel et al. | Apr 2011 | A1 |
20110137286 | Mudd et al. | Jun 2011 | A1 |
20110160674 | Holmes et al. | Jun 2011 | A1 |
20110202014 | Mutzbauer | Aug 2011 | A1 |
20130131632 | Mudd et al. | May 2013 | A1 |
20130131633 | Mudd et al. | May 2013 | A1 |
20130274670 | Mudd et al. | Oct 2013 | A1 |
Number | Date | Country |
---|---|---|
0362484 | Apr 1990 | EP |
1051988 | Nov 2000 | EP |
1486218 | Dec 2004 | EP |
1859827 | Nov 2007 | EP |
1923086 | May 2008 | EP |
2335755 | Jun 2011 | EP |
2622457 | May 1989 | FR |
9948601 | Sep 1999 | WO |
2005095225 | Oct 2005 | WO |
2008019265 | Feb 2008 | WO |
2008079824 | Jul 2008 | WO |
2008148071 | Dec 2008 | WO |
2009003135 | Dec 2008 | WO |
2009098666 | Aug 2009 | WO |
2009158145 | Dec 2009 | WO |
Entry |
---|
Davidenko et al., “Collagen-hyaluronic acid scaffolds for adipose tissue engineering”, ACTA Biomaterialia, vol. 6, No. 10, Oct. 1, 2010, pp. 3957-3968, XP055055114. |
Park et al., “Biological characterization of EDC-crosslinked collagen-hyaluronic acid matrix in dermal tissue restoration”, Biomaterials, Elsevier Science Publishiers BV, vol. 24, No. 9, Apr. 1, 2003, pp. 1631-1641, XP004404219. |
Wang et al., “In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermall filler injections in photodamaged human skin.”, Archives of Dermatology, American Medical Association, US, vol. 143, No. 2, Feb. 1, 2007, pp. 155-163, XP002574140. |
Number | Date | Country | |
---|---|---|---|
20140052059 A1 | Feb 2014 | US |
Number | Date | Country | |
---|---|---|---|
61683157 | Aug 2012 | US |